We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
51
Evolent Health
EVH
$642M
$40.6M 0.56%
3,273,325
-1,755,038
-35% -$20.6M
BIO icon
52
Bio-Rad Laboratories Class A
BIO
$8.12B
$40.3M 0.56%
78,186
-1,685
-2% -$853K
INSM icon
53
Insmed
INSM
$23.5B
$39.2M 0.54%
1,220,169
-236,005
-16% -$6.78M
ARVN icon
54
Arvinas
ARVN
$519M
$38.8M 0.54%
1,641,503
+59,800
+4% +$1.73M
PACB icon
55
Pacific Biosciences
PACB
$419M
$38.5M 0.53%
3,904,467
-4,459,274
-53% -$25.7M
BAX icon
56
Baxter International
BAX
$11.4B
$38.2M 0.53%
474,623
-150,872
-24% -$12.7M
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$36.4M 0.5%
3,850,000
– –
TNDM icon
58
Tandem Diabetes Care
TNDM
$1.19B
$35.6M 0.49%
313,444
+81,605
+35% +$8.57M
INSP icon
59
Inspire Medical Systems
INSP
$1.48B
$35.2M 0.49%
272,983
+28,733
+12% +$3.17M
SWAV
60
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$35M 0.48%
461,253
+43,164
+10% +$2.45M
AXNX
61
DELISTED
Axonics, Inc. Common Stock
AXNX
$32.9M 0.45%
644,944
+128,516
+25% +$5.36M
TMO icon
62
Thermo Fisher Scientific
TMO
$195B
$31.3M 0.43%
70,865
+1,374
+2% +$568K
EXAS
63
DELISTED
Exact Sciences
EXAS
$31M 0.43%
+304,490
New +$26.3M
IDXX icon
64
Idexx Laboratories
IDXX
$44.5B
$30.8M 0.43%
78,398
+4,791
+7% +$1.77M
ZBH icon
65
Zimmer Biomet
ZBH
$17.4B
$30.7M 0.42%
232,512
-1,821
-0.8% -$238K
HCM icon
66
HUTCHMED
HCM
$1.92B
$30.6M 0.42%
947,674
– –
MOH icon
67
Molina Healthcare
MOH
$11.8B
$30.1M 0.42%
164,572
– –
ICPT
68
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$29.2M 0.4%
704,976
– –
VYGR icon
69
Voyager Therapeutics
VYGR
$188M
$28.9M 0.4%
2,712,083
– –
LVGO
70
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$28.5M 0.39%
203,329
-53,929
-21% -$6.57M
ABMD
71
DELISTED
Abiomed Inc
ABMD
$28.1M 0.39%
101,398
+4,699
+5% +$1.35M
DVA icon
72
DaVita
DVA
$15.2B
$28M 0.39%
326,400
+26,200
+9% +$2.24M
ALGN icon
73
Align Technology
ALGN
$12.5B
$27.7M 0.38%
84,635
-14,234
-14% -$4.35M
VEEV icon
74
Veeva Systems
VEEV
$31.8B
$26.8M 0.37%
95,367
+32,311
+51% +$8.52M
TFX icon
75
Teleflex
TFX
$5.94B
$26.8M 0.37%
78,644
+311
+0.4% +$115K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.